ContractGlobal Collaboration and License Agreement • December 18th, 2020
Contract Type FiledDecember 18th, 2020• Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders